Genetic Technologies (Australia) Today
| GTG Stock | 0.04 0.00 0.00% |
Performance1 of 100
| Odds Of DistressOver 86
|
Genetic Technologies is selling for under 0.039 as of the 28th of November 2024; that is No Change since the beginning of the trading day. The stock's last reported lowest price was 0.039. Genetic Technologies has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. Equity ratings for Genetic Technologies are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 29th of October 2024 and ending today, the 28th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | Category Healthcare | Classification Health Care |
Genetic Technologies is entity of Australia. It is traded as Stock on AU exchange. The company has 145.42 M outstanding shares. More on Genetic Technologies
Moving against Genetic Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Genetic Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Genetic Technologies' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Genetic Technologies or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Thematic Idea | IT (View all Themes) | ||||
| Business Concentration | Life Sciences Tools & Services, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, IT, Health Care, Life Sciences Tools & Services, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Computing (View all Sectors) | ||||
Genetic Technologies' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Genetic Technologies' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Debt LevelsGenetic Technologies can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Genetic Technologies' financial leverage. It provides some insight into what part of Genetic Technologies' total assets is financed by creditors.
| |||||
Genetic Technologies (GTG) is traded on Australian Securities Exchange in Australia and employs 55 people. Genetic Technologies is listed under Life Sciences Tools & Services category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 5.67 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Genetic Technologies's market, we take the total number of its shares issued and multiply it by Genetic Technologies's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Genetic Technologies operates under Life Sciences Tools & Services sector and is part of Health Care industry. The entity has 145.42 M outstanding shares.
Genetic Technologies generates negative cash flow from operations
Check Genetic Technologies Probability Of Bankruptcy
Ownership AllocationGenetic Technologies has a total of 145.42 Million outstanding shares. Genetic Technologies retains 5.56 (percent) of its outstanding shares held by insiders and 0.0 (percent) owned by outside corporations. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Genetic Ownership Details
Genetic Technologies Risk Profiles
Although Genetic Technologies' alpha and beta are two of the key measurements used to evaluate Genetic Technologies' performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 3.19 | |||
| Semi Deviation | 4.12 | |||
| Standard Deviation | 4.89 | |||
| Variance | 23.93 |
Genetic Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Genetic Technologies without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Stock Tickers Now
Stock TickersUse high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |
| All Next | Launch Module |
Genetic Technologies Corporate Management
Elected by the shareholders, the Genetic Technologies' board of directors comprises two types of representatives: Genetic Technologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Genetic. The board's role is to monitor Genetic Technologies' management team and ensure that shareholders' interests are well served. Genetic Technologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Genetic Technologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kevin Camilleri | Chief EasyDNA | Profile | |
| CPA BCom | Chief Secretary | Profile | |
| Bus FCI | Consultant | Profile | |
| Simon Morriss | Chief Officer | Profile |
Additional Tools for Genetic Stock Analysis
When running Genetic Technologies' price analysis, check to measure Genetic Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genetic Technologies is operating at the current time. Most of Genetic Technologies' value examination focuses on studying past and present price action to predict the probability of Genetic Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genetic Technologies' price. Additionally, you may evaluate how the addition of Genetic Technologies to your portfolios can decrease your overall portfolio volatility.